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Abstract 
Background: Myocardial fibrosis is an important pathophysiologic mechanism underlying the 
development of heart failure (HF). Given the biochemical targets of sacubitril/valsartan, we 
hypothesized that circulating biomarkers reflecting the mechanisms that determine extracellular 
matrix (ECM) homeostasis, including collagen synthesis, processing and degradation are altered 
by sacubitril/valsartan in comparison to enalapril. 
Objectives: Examine the effects of sacubitril/valsartan on biomarkers of ECM homeostasis and the 
association between the rate of primary composite outcome (CV death or HF hospitalization) and 
these biomarkers. 
Methods: Biomarkers at baseline (2067 patients) and both baseline and 8 months after 
randomization (1776 patients) included aldosterone, sST2, TIMP-1, MMP-2, MMP-9, Gal-3, 
PINP, and PIIINP. The effects of sacubitril/valsartan on biomarkers were compared with enalapril. 
Baseline biomarker values and changes from baseline to 8 months were related to primary 
outcome. 
Results: At baseline, profibrotic biomarkers aldosterone, sST2, TIMP-1, Gal-3, PINP, PIIINP were 
higher and biomarkers associated with collagen degradation, MMP-2, MMP-9 were lower than 
published referent control values. Eight months after randomization, aldosterone, sST2, TIMP-1, 
MMP-9, PINP, and PIIINP had decreased more in the sacubitril/valsartan than enalapril group. At 
baseline, higher values of sST-2, TIMP-1, and PIIINP were associated with higher primary 
outcome rates. Changes from baseline to 8 months in sST-2 and TIMP-1 were associated with a 
change in outcomes. 
Conclusions: Biomarkers associated with profibrotic signaling are altered in HFrEF; 
sacubitril/valsartan significantly decreased many of these biomarkers; and these biomarkers have 
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important prognostic value. These findings suggest that sacubitril/valsartan may reduce profibrotic 
signaling which may contribute to the improved outcomes. 
Word Count: 250 
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Condensed Abstract 
We tested the hypothesis that circulating biomarkers that reflect mechanisms of extracellular 
matrix homeostasis would be abnormal in patients with HFrEF enrolled in the PARADIGM-HF 
trial, have prognostic value, and reflect the therapeutic effect of sacubitril/valsartan. Biomarkers 
associated with profibrotic signaling are altered in HFrEF and sacubitril/valsartan significantly 
decreased these biomarkers. Baseline and change in biomarkers associated with profibrotic 
signaling have important prognostic value. These findings suggest that sacubitril/valsartan may 
reduce profibrotic signaling which may contribute to the improved outcomes. 
Word Count: 72 words 
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Abbreviations 
HFrEF- Heart failure with a reduced ejection fraction 
sST2- soluble ST-2 
TIMP- Tissue inhibitor of matrix metalloproteinase 
MMP- matrix metalloproteinase 
Gal-3 – Galectin-3 
PINP- n-terminal propeptide of collagen I 
PIIINP- n-terminal propeptide of collagen III 
CV- cardiovascular 
COV - coefficient of variance 
LOD - lower limit of detection 
LLOQ - lower limit of quantitation 
hsTnT – high sensitivity tropinin 
HFH – herat failure hospitalization 
ICD - implantable cardiac defibrillator 
CRT - cardiac resynchronization therapy 
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LV = left ventricular 
HF = heart failure 
ACEi = angiotensin converting enzyme inhibitor 
ARB = angiotensin receptor blocker 
BNP = b-type natriuretic peptide 
NT-proBNP = n-terminal pro BNP 
NYHA = New York Heart Association 
 
Twitter Account: @UofGICAMS 
Twitter message: Biomarkers that reflect ECM homeostasis/fibrosis are abnormal in HFrEF 
patients, have prognostic value, and are altered by sacubitril/valsartan. 
144 characters including spaces. 
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Introduction 
 Myocardial fibrosis is an important pathophysiologic mechanism involved in the development 
and progression of chronic heart failure (CHF) (1-3). The extent and distribution of myocardial 
fibrosis is the aggregate result of the homeostatic processes that govern collagen metabolism (3-
6). These include collagen synthesis, processing, and degradation. Collagen synthesis by 
myocardial fibroblasts is affected by hemodynamic, neurohumoral, metabolic and other profibrotic 
and anti-fibrotic determinants that are activated in diseases such as CHF (4-6). For example, 
collagen synthesis by fibroblasts is increased by aldosterone, soluble ST-2 (sST-2), galectin-3 
(Gal-3) and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). Each of these 
proteins/peptides are present in sufficient quantities to be measured in the plasma of referent 
control and CHF patients (3, 7-9). Newly synthesized collagen must be processed by removing the 
C-terminal and N-terminal propeptides. The N-terminal propeptide of collagen I (PINP) and 
collagen III (PIIINP) can be measured in the serum of control and CHF patients (7-9). Collagen 
can be further processed (and degraded) by matrix metalloproteinases (MMP) such as MMP-2 and 
-9. 
 In a recent review, Ferreira et. al. summarized the few studies that have examined circulating 
biomarkers that reflect extracellular matrix (ECM) homeostasis in patients with heart failure and 
a reduced ejection fraction (HFrEF) and that examined the relationship between these biomarkers 
and prognosis or response to therapy (10). Of these, only four studies, with a limited number of 
circulating biomarkers that reflect some aspect of ECM homeostasis, had sample sizes in excess 
of 200 subjects. These studies demonstrated variable prognostic value of collagen propeptides, 
collagen teleopeptides, and MMP-1 on clinical outcomes. MMP-1 and PIIINP had the most 
significant relationship to outcomes and were decreased with treatment with mineralocorticoid 
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receptor antagonists (MRAs) and cardiac resynchronization therapy. However, these studies did 
not examine a comprehensive panel of biomarkers that represent determinants of ECM 
homeostasis, nor did they adjust these analyses for clinical/demographic parameters, other 
biomarkers with known prognostic value (natriuretic peptides and troponin), or other ECM 
homeostasis biomarkers. 
 The Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality 
and Morbidity in Heart Failure trial (PARADIGM-HF) provided a unique opportunity to examine 
a panel of biomarkers that reflect ECM homeostasis in a large cohort of well characterized HFrEF 
patients that included long term outcome data. In the current analysis of PARADIGM-HF, the 
following hypotheses were examined: 1) circulating biomarkers that reflect the determinants of 
ECM homeostasis are abnormal in patients with HFrEF; 2) both baseline and change from baseline 
values in biomarkers that represent determinants of ECM homeostasis have incremental prognostic 
value after adjusting for clinical/demographic parameters and other biomarkers with known 
prognostic value (natriuretic peptides and troponin); 3) treatment with sacubitril/valsartan leads to 
changes in these biomarkers that are compatible with an anti-fibrotic effect. 
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Methods 
Study Design and Procedures 
 The design and primary results of PARADIGM-HF have been extensively described elsewhere 
(11-13). Patients with chronic HF, NYHA class II–IV symptoms; elevated plasma levels of 
natriuretic peptides, and systolic LV dysfunction (LVEF ≤ 40%) were eligible for randomization 
in PARADIGM-HF. The primary outcome was a composite of death from cardiovascular (CV) 
causes or a first hospitalization for heart failure (HFH). The relationship between these CV 
outcomes and eight plasma biomarkers (described below) was examined. 
 
Patient Population 
 For logistical reasons, centers in Asia/South Pacific and in South America did not participate 
in the biomarker ancillary study. Patients recruited at selected North American and European sites 
in the PARADIGM-HF trial were invited to participate in the biomarker study. A total of 2067 
participants were enrolled and had 8 biomarkers measured at baseline (prior to run-in). Of these 
participants, 1776 had a second measurement of these biomarkers at 8 months after randomization 
(Table 1). Unless stated otherwise, all analyses of baseline data are obtained from the full cohort 
of 2067 patients, while analyses of post-baseline biomarkers are obtained from the 1776 patients 
with data available at both time points. 
 
Biomarkers 
 Aldosterone, TIMP-1, MMP-2, and MMP-9, were assayed in plasma and sST2, Gal-3, PINP, 
and PIIINP in serum. Samples were collected, stored, and transferred to the central lab as 
previously described (13). The following assays were used: Aldosterone (DiaSorin Liaison assay, 
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Saluggia, Italy); TIMP-1 (R&D Systems, Minneapolis, MN), MMP-2 and MMP-9 (Meso Scale 
Discovery, Gaithersburg, MD), Galectin-3 (BG Medicine , Waltham, MA ; PINP, PIIINP (Orion 
Diagnostica, Espoo, Finland); Soluble ST2 (Critical Diagnostics Presage® assay, San Diego, CA). 
The coefficient of variance (COV), lower limit of detection (LOD), or lower limit of quantitation 
(LLOQ) and measuring range for each biomarker are presented in appendix Table 1. Analyses 
were adjusted for: B-type natriuretic peptide (BNP; Siemens Centaur assay, Tarrytown, NY), N-
terminal propeptide of BNP (NT-proBNP; Roche Diagnostics, Indianapolis, IN) and high 
sensitivity troponin T (hs-TnT; Roche Diagnostics GmbH, Mannheim, Germany). 
 Changes in biomarkers from baseline to 8-months were compared between treatment groups: 
enalapril and sacubitril /valsartan. Baseline values were related to the rate of primary outcome, CV 
death and HF hospitalization for the trial as a whole. Biomarker changes from baseline to 8-months 
were related to the rate of primary outcome using a landmark analysis beginning after the eighth 
month time point. 
 
Statistical Analysis 
 Baseline biomarker data were compared qualitatively with referent control values (7, 14-29). 
Referent control values were presented for comparison as median (± interquartile ranges [IQR]). 
 Biomarker levels at baseline and 8-month post-randomization are displayed using median 
(IQR). Baseline characteristics of PARADIGM-HF patients (with or without a biomarker 
measurements) were summarized using mean ± standard deviation, median (IQR), or frequency 
and percentages, as appropriate, with comparisons between the two groups conducted using t-test, 
Wilcoxon rank-sum test, and Pearson’s chi-squared test, respectively. Biomarker values at baseline 
and month 8 post-randomization and corresponding changes from baseline were summarized for 
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each treatment group using median (IQR), using quantile regression, adjusting for the baseline 
value, to compare the changes between treatment groups. Similarly, biomarkers values were also 
summarized using geometric means, with percent changes from baseline compared using linear 
regression with log-transformed biomarker values as the outcome and adjusting for log-
transformed baseline biomarker. The proportion of patients with biomarker levels that exceeded 
the referent control median value was reported and compared using unadjusted logistic regression. 
Additionally, the proportions of patients in each treatment group with a biomarker increase or 
decrease from baseline of specific magnitude were reported. 
 The relationships between baseline biomarkers and incident rates of subsequent clinical 
outcomes were assessed using restricted cubic spline models with three knots in models. These 
baseline relationships were adjusted using the following parameters applied individually or in 
combination: baseline covariates (defined below); BNP and NT-proBNP; hs-TnT; randomized 
treatment group (enalapril or sacubitril/valsartan), and baseline values of all 8 fibrosis-related 
biomarkers (aldosterone, TIMP-1, MMP-2, MMP-9, sST2, Gal-3, PINP, and PIIINP). In addition, 
for the change from baseline analyses, baseline values of each biomarker were also used for 
adjustments. Baseline characteristics listed in Table 1 (baseline covariates) included: age, sex, 
geographic region, body mass index, New York Heart Association (NYHA) class, left ventricular 
ejection fraction (LVEF), prior HFH, hypertension, diabetes, ischemic etiology, prior myocardial 
infarction, atrial fibrillation, heart rate, systolic blood pressure, creatinine, prior stroke, implantable 
cardioverter defibrillator (ICD), cardiac resynchronization therapy (CRT), prior use of an 
angiotensin converting enzyme inhibitor (ACEI), prior use of an angiotensin receptor blocker 
(ARB), diuretics, beta-blockers, digoxin, mineralocorticoid receptor antagonist (MRA). 
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 Previous studies using the PARADIGM-HF study population have demonstrated that baseline 
covariates, BNP, NT-proBNP, hs-TnT and randomized treatment group were predictive of patient 
outcomes. Therefore, all of these parameters were used to adjust the analytic models that examined 
the relationship between the 8 profibrotic biomarkers and outcomes. These are the primary 
analyses presented in the results below. The predictive value that an individual profibrotic 
biomarker added as a baseline value to these models was also examined as a secondary analysis 
using a C-statistic model described below. The change from baseline to 8 months after 
randomization of all 8 fibrosis-related biomarkers was not added as a covariate adjustment to the 
analysis examining the relationship between change from baseline and outcomes because the 
number of events that occurred after the landmark time were limited and would not support a 
robust statistical analysis. 
 Adjusted hazard ratios were produced using Cox proportional hazards models using both 
untransformed and log-transformed biomarkers. Landmark analyses of proportional changes in 
biomarkers from baseline to month 8 vs subsequent clinical outcomes were assessed using adjusted 
Cox proportional hazards models. All events that occurred between baseline and month 8 were 
excluded from this landmark analysis examining events subsequent to month 8. Effect 
modification by randomized therapy was assessed via interaction terms for all clinical outcomes. 
Harrell’s C-statistics for models with and without 5 sets of covariate conditions were tested for 
both the primary endpoint and CV mortality: baseline covariates (M1); M1 plus BNP NT-proBNP 
and hs-TnT (M2); M2 plus TIMP-1 (M3), M2 plus all 8 profibrotic biomarkers (M4), M4 minus 
M1 (M5). 
All analyses were conducted using STATA version 14 (College Station, TX). P-values < 0.05 were 
considered to be statistically significant, and no adjustments were made for multiple comparisons.  
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Results 
Baseline Characteristics and Outcomes 
 The characteristics of the study population are presented in Table 1, appendix tables 5 & 6. 
Patients who participated in the biomarker study and patients who did not participate in the 
biomarker study had several statistically significant differences; all analyses were adjusted for each 
of the characteristics listed in Table 1 that differed significantly between the 2 groups. Within the 
biomarker study group, those randomized to enalapril vs sacubitril/valsartan had very few 
differences in any of the baseline parameters listed in Table 1. Three parameters had clinically 
minor but statistically significant differences. Compared with patients taking enalapril, patients 
taking sacubitril/valsartan had less prior use of a MRA (48% vs. 42%, p=0.008), less prior ARB 
use (22% vs. 18%, p=0.015), more prior ACEi use (79% vs. 83%, p=0.019). 
 
Baseline Biomarker Values vs Referent Controls 
 Table 2 shows the comparison of the baseline values of biomarkers in patients enrolled in 
PARADIGM-HF with published values of these biomarkers from referent control subjects. This 
analysis showed that, compared to referent controls, patients with HFrEF had increased 
aldosterone, sST2, Galectin-3, TIMP-1, PINP, PIIINP and decreased MMP-2 and -9. The percent 
of the PARADIGM-HF patients that had values of aldosterone, sST2, Galectin-3, TIMP-1, PINP, 
PIIINP greater than the referent control median and values of MMP-2 and -9 below the referent 
control median were more than 65% for all 8 biomarkers; > 85% for 4 of the biomarkers. 
 
Effects of Treatment with Sacubitril / valsartan versus Enalapril on Biomarkers 
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 Figure 1 graphically displays the effects of treatment with enalapril versus sacubitril/valsartan 
on the geometric mean of biomarkers from baseline value to 8 months after randomization 
expressed as percent change. Aldosterone, sST2, MMP-9, TIMP-1, and PINP were signficantly 
reduced with sacubitril/valsartan compared with enalapril treatment (all comparisons p < 0.05 
sacubitril/valsartan vs. enalapril) adjusted for baseline biomarker values. Compared to enalapril, 
sacubitril/valsartan treatment decreased aldosterone by -6% (95% CI -11% to -1%), sST2: -7% (-
9% to -4%), MMP-9: -8% (-14% to -2%), TIMP-1: -4% (-7% to -1%), PINP: -6% (-10% to -3%). 
There were no statistically significant differences between treatment groups with respect to 
changes in MMP-2, galectin-3, and PIIINP. 
 An additional analysis was performed in which baseline systolic blood pressure and change in 
systolic blood pressure was used as a covariate in analyses that compared changes in biomarkers 
in the two treatment groups. These analyses suggested that the differential effect of 
sacubitril/valsartan on the profibrotic biomarkers were independent of the change in blood 
pressure. These data are presented in Appendix Table 7. 
 
Baseline Biomarker Values vs Outcomes 
 The relationships between baseline values of the 8 profibrotic biomarkers, the risk of the 
primary outcome (combination of CV death and HF hospitalization) and the risk of CV death alone 
are presented in Figure 2 and Table 3. The higher the baseline value of sST2, TIMP-1 or PIIINP, 
the higher the subsequent rates of CV death and HF hospitalizations. These relationships were 
statistically significant after adjustment for baseline covariates, the biomarkers BNP, NT-proBNP; 
hs-TnT and randomized treatment group. By contrast, there were no relationships between 
outcomes and aldosterone, MMP-2, MMP-9, Gal-3 or PINP. 
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 Next, we addressed the issue of whether any individual profibrotic biomarker added prognostic 
value independent of the other profibrotic biomarkers, and independent of baseline covariates, 
BNP, NT-proBNP; hs-TnT; and randomized treatment group using a C-statistical analysis. 
Supplemental Appendix Table 3 shows the relationship between baseline values of each of the 8 
profibrotic biomarkers and the primary outcome and CV death after adjustment of the model for 
all 8 biomarkers. TIMP-1 had prognostic significance independent of the other 7 biomarkers and 
the other adjustment variables. For TIMP-1, the HR (95% CI) for the primary outcome was 1.20 
(1.03-1.38) p=0.017 and for CV death was 1.43 (1.14-1.79) p=0.002. Thus, in these patients with 
HFrEF, baseline values of TIMP-1, independent of the other 7 profibrotic biomarkers and 
independent of BNP, NT-proBNP and hs-TnT, predicted patient outcomes. Using sequential 
modeling and a C-statistical method, the additional prognostic significance of each adjustment 
parameter was quantified (Supplemental Appendix Table 4). Again, of all 8 profibrotic 
biomarkers, only TIMP-1 improved the C-statistic. 
 
Relationship Between Change in Biomarker from Baseline and Outcomes 
 The relationships between change from baseline to 8 months after randomization of the 8 
profibrotic biomarkers, the risk of the primary outcome (composite of CV death or HF 
hospitalization) and the risk of CV death alone are presented in Figure 3 and Table 3. The greater 
the decrease from baseline value of sST2 the greater the reduction in the subsequent rates of the 
primary outcome. The greater the decrease from baseline value of TIMP-1 the greater the reduction 
in the subsequent rates of CV Death. These relationships were statistically significant after 
adjustment for baseline covariates, BNP, NT-proBNP, hs-TnT, and randomized treatment group. 
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By contrast, there were no relationships between outcomes and aldosterone, MMP-2, MMP-9, Gal-
3, PINP or PIIINP.  
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Discussion 
 
 Biomarker data presented in the current analysis of the PARADIGM–HF study support four 
conclusions. First, biomarkers that reflect mechanisms of ECM homeostasis (aldosterone, sST2, 
TIMP-1, MMP-2, MMP-9, Gal-3) and collagen synthesis (PINP, PIIINP) are altered in patients 
with HFrEF indicating the presence of profibrotic signaling. Second, treatment with 
sacubitril/valsartan alters these biomarkers of ECM homeostasis, decreasing determinants of 
collagen synthesis and processing, suggesting a decrease in the profibrotic state. Third, there is a 
significant relationship between baseline values of sST-2, TIMP-1, PIIINP and the rate of primary 
composite outcome (CV death or HF hospitalization) in PARADIGM-HF patients. Fourth, there 
is a significant relationship between a change from baseline to 8 months after randomization values 
of sST-2, TIMP-1 and the rate of cardiovascular outcomes in PARADIGM-HF patients. In 
aggregate, these data suggest that one mechanism by which sacubitril/valsartan may exert a 
beneficial outcome in HFrEF patients may be related to a reduction in profibrotic signaling. The 
current study raises the possibility that further addition of biomarkers that reflect determinants of 
ECM homeostasis might improve these prognostic models. Clearly however, additional studies 
must be performed. 
 
Importance of myocardial fibrosis in HFrEF patients 
 Both replacement/reparative fibrosis, which replaces foci of necrotic or apoptotic 
cardiomyocytes, and reactive fibrosis, which occurs in response to increased metabolic and 
hemodynamic load, are two processes that may contribute to the structural and functional cardiac 
changes seen in patients with HFrEF (1,2,4). In HFrEF, these structural changes are associated 
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with abnormalities in both systolic and diastolic function, may increase the propensity to 
arrhythmias (both atrial and ventricular) and may alter myocardial perfusion (30-32). The presence 
and extent of fibrosis has been shown to be associated with changes in morbidity and mortality 
rates in patients with heart failure (1,2,33). Under some clinical circumstances, regression of 
fibrosis may is associated with lower morbidity and mortality. Examples include HFrEF patients 
that are treated with MRAs (34,35), patients with aortic valve stenosis that undergo aortic valve 
replacement , and patients with HFrEF that undergo left ventricular assist device implantation (36-
39). Therefore, the ability to noninvasively assess the presence and extent of the profibrotic state, 
and treatment-induced changes in this state, using circulating biomarkers may have clinical 
application. 
 While it is not possible at this point to directly measure collagen volume fraction using 
circulating biomarkers, it is possible to measure biomarkers that reflect changes in the 
determinants of ECM homeostasis. In myocardial samples from both patients with heart failure 
and animal models of heart failure, a correlation between circulating biomarkers and collagen 
volume fraction have been found (1,3,10). These correlative data support the utility of measuring 
circulating biomarkers. 
 
Biomarkers that reflect mechanisms of ECM homeostasis 
 The homeostatic processes that govern ECM collagen metabolism include determinants of 
collagen synthesis, processing, cross-linking, and degradation (4). Collagen synthesis by 
myocardial fibroblasts is affected by hemodynamic, neurohumoral, metabolic and other profibrotic 
and anti-fibrotic determinants (Figure 4). For example, collagen synthesis by fibroblasts (and 
possibly the activation of fibroblasts) can be induced by increased aldosterone, Gal-3, and 
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increased hemodynamic and metabolic load. However, additional steps after collagen synthesis 
must occur before myocardial fibrosis develops. For example, newly synthesized collagen must 
be processed by removing the C-terminal and N-terminal propeptides and then cross-linked before 
it can form a structural insoluble collagen fiber. PINP and PIIINP can be measured in the plasma 
of control and HF patients and when increased indicate an increase in synthesis rate. Structural 
insoluble collagen fibers can be further processed (and degraded) by matrix metalloproteinases 
such as MMP-2 and -9. The activity of MMPs are further modulated by the endogenous inhibitors 
of MMPs, the TIMPs, such as TIMP-1. A number of MMPs and TIMPs secreted by myocardial 
fibroblasts can be measured in the circulation and have been found to be altered in heart failure 
patients; when MMP’s are decreased and/or TIMPs are increased, there is a decrease in collagen 
degradation and an increase in collagen content. Thus, the extent and distribution of myocardial 
fibrosis, results from the balance between collagen synthesis, processing and degradation. 
 However, while individual biomarkers have been studied in HFrEF, a comprehensive 
examination of all of these profibrotic biomarkers, simultaneously, in a large group of HFrEF 
patients has not been performed before. Importantly, it has not been previously possible to relate 
biomarkers to prognosis, and to comprehensively examine the effects of treatment on a full range 
of markers of ECM homeostasis. Analyses from the current study addressed both of these issues. 
 
Biomarkers and Prognosis 
 A large number of prognostic models have been developed in HFrEF and have been recently 
reviewed (40-42). In addition, biomarkers such as BNP, NT-proBNP and hs-TnT have been shown 
to provide additional prognostic value to these clinical risk scores. The current study suggests that 
the further addition of biomarkers that reflect determinants of ECM homeostasis may improve 
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these prognostic models. In the current study, three profibrotic biomarkers had significant 
prognostic importance: sST2, TIMP-1 and PIIINP in a fashion that was independent of clinical 
parameters, natriuretic peptides and troponin T and treatment effects. Furthermore, TIMP-1 had 
prognostic significance independent of the other seven biomarkers. Thus, in this patient population 
of HFrEF, baseline values of TIMP-1, independent of the other seven profibrotic biomarkers and 
independent of BNP, NT-proBNP and hs-TnT, predicted patient outcomes. 
 
Effects of Sacubitril/valsartan on Biomarkers 
 Previous studies using PARADIGM-HF data showed that treatment with sacubitril/valsartan 
decreased NT-proBNP and HS troponin T, but had no effect on GDF-15 (13,43). However, the 
current study is the first to show that sacubitril/valsartan alters a panel of profibrotic biomarkers 
the reflect changes in determinants of collagen synthesis, processing and degradation. In addition 
these effects were independent of changes in clinical parameters, BNP, NT-proBNP and hs-TnT. 
To date the only other drug that has been shown to alter any profibrotic biomarkers were the MRAs 
(both spirololactone and eplerenone) which decreased PIIINP. No other large cohort of well 
characterized HFrEF patients coupled with long term outcome data has shown the effects of drug 
therapy on a reasonably comprehensive panel of profibrotic biomarkers. 
 
Limitations 
 The referent control data were assembled from “historic controls” aggregated from previous 
publications, and were not contemporaneous or obtained from an enrolled referent control cohort 
as part of PARADIGM- HF. While this is certainly a limitation, the validity of the comparisons 
made between PARADIGM-HF patients and referent controls is supported by the extensive review 
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(Appendix Table 2), the similarity in assay techniques, and similarity on demographics of referent 
subjects with respect to age, gender, co-morbidities but the absence of heart failure. 
 Circulating biomarkers were measured using plasma or serum peripheral venous samples. 
Therefore, the myocardium, particularly the LV myocardium is only one potential source for the 
proteins/peptides that were measured. However, the exclusion criteria used in PARADIGM-HF 
served to minimize the impact of most of the other potential organ sources of these biomarkers. 
For example, renal function was limited to those with modest reductions in eGFR, patients with 
chronic hepatic, bone, or skin disease, systemic inflammatory diseases, malignancies, and 
pregnancy were excluded. Under these circumstances, measured biomarkers may be substantially 
influenced by myocardial sources. Similar approaches have been used in many other prospective 
studies. 
 Given the exploratory nature of this analysis, multiple comparisons were made without formal 
adjustment for the number of biomarkers, outcomes, and time points under consideration. As such, 
type-I errors may be present, though we note that many reported results would remain significant 
at alpha=0.006, reflecting a Bonferroni correction (0.05/8) for the number of biomarkers reported. 
 
Conclusions 
 Biomarkers that reflect mechanisms of ECM homeostasis and collagen synthesis are altered in 
patients with HFrEF, in a profibrotic manner. Baseline and change from baseline values of 
biomarkers associated with profibrotic signaling have important prognostic value. 
Sacubitril/valsartan significantly decreased these biomarkers. In aggregate, these data suggest that 
one mechanism by which sacubitril/valsartan may exert a beneficial outcome in HFrEF patients 
may be related to processes associated with changes in these biomarkers. 
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Perspectives 
Clinical Competencies 
Competency in Medical Knowledge: Myocardial fibrosis is an important pathophysiologic 
mechanism underlying the development of and the degree of illness in patients with heart failure 
and a reduced ejection fraction (HFrEF). 
Competency in Patient Care: The appropriate use of sacubitril/valsartan in patients with HFrEF 
will result in a significant reduction in patient morbidity and mortality and these outcomes may 
be related to a change in the profibrotic signaling present in patients with HFrEF. 
Translational Outlook implications: 
Translational Outlook 1: The data presented in this manuscript examining the utility of 
profibrotic biomarkers will facilitate the development of new strategies for the management and 
treatment of patients with HFrEF. 
Translational Outlook 2: The data presented in this manuscript examining the changes in 
profibrotic biomarkers that result from pharmacologic treatment and their resultant effects on 
morbidity and mortality markedly improve the understanding of the mechanism of action of 
sacubitril/valsartan. 
Clinical Perspectives: 
No previous analysis has been able to address the following critical clinically important issues: 
1- Are plasma biomarkers that reflect mechanisms of extracellular matrix (ECM) homeostasis 
(aldosterone, sST2, TIMP-1, MMP-2, MMP-9 and Gal-3), collagen synthesis and processing 
(PINP, PIIINP) (“profibrotic biomarkers”), abnormal in patients with HFrEF? 
2- Does treatment of HFrEF patients with sacubitril/valsartan reduce profibrotic biomarkers 
more than treatment with enalapril? 
3) Is there a relationship between baseline values and change from baseline values of profibrotic 
biomarkers and a change in the morbidity and mortality in patients with HFrEF? 
The answers to these questions have an important and practical influence on our understanding 
of CHF pathophysiology, use of biomarkers to facilitate treatment, and our understanding of the 
mechanism of action of sacubitril/valsartan. 
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Figure Legends 
 
Figure 1: Effects of treatment with enalapril (red bars) versus sacubitril / valsartan (green bars) on 
the geometric mean percent change in biomarkers from baseline to 8 months after randomization. 
* = p < 0.05 versus enalapril. Sacubitril / valsartan treatment was associated with a significantly 
larger decrease in aldosterone (aldo), soluble ST2 (sST2) matrix metalloproteinase (MMP)-9, 
tissue inhibitor of MMP (TIMP) -1, and n-terminal propeptide of collagen I (PINP) than treatment 
with enalapril. 
 
Figure 2: Baseline Biomarker vs Outcome The risk of the primary outcome (combination of 
cardiovascular [CV] death and heart failure [HF] hospitalization) and the risk of CV death alone 
increased with increasing baseline values of soluble ST2 (sST2) (Panels A&B), tissue inhibitor of 
matrix metalloproteinase (TIMP)-1(Panels C&D), and n-terminal propeptide of collagen III 
(PIIINP) (Panels E&F). The higher the baseline value of sST2, TIMP-1 or PIIINP, the higher the 
subsequent rates of CV death and HF hospitalizations. These relationships were significant after 
adjustment for treatment and baseline covariates including BNP, NT-proBNP and hsTnT. 
 
Figure 3: Biomarker Change from Baseline vs Outcome. 
Panel A: Change in sST2 from baseline to 8 months after randomization was associated with a 
significant change in CV death and HF hospitalization after adjustment for treatment, baseline 
covariates including BNP, NT-proBNP and hsTnT, and baseline value of sST2; there was a trend 
in the relationship between change in sST2 and CV death but this did not reach statistical 
significance (Panel B). Panel D: Change in TIMP-1 from baseline to 8 months after randomization 
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was associated with a change in CV death after adjustment for treatment, baseline covariates 
including BNP, NT-proBNP and hsTnT, and baseline value of TIMP-1; there was a trend in the 
relationship between change in sST2 and CV death but this did not reach statistical significance 
(Panel C). 
 
Central Illustration Figure 4: Biomarkers that reflect determinants of a profibrotic state in heart 
failure with a reduced ejection fraction (HFrEF) and the effects of sacubitril / valsartan on these 
biomarkers. In patients with HFrEF increased aldosterone, galectin-3 and metabolic/hemodynamic 
load activate fibroblasts to increase collagen synthesis as evidenced by increased PINP, PIIINP 
and sST2. Activated fibroblasts secrete proteins and peptides that reduce collagen degradation 
such as decreased MMP-2 and 9 and increased TIMP-1. The changes in these biomarkers that 
reflect determinants of profibrotic state are indicated in red type. Treatment with sacubitril / 
valsartan alters these biomarkers that reflect determinants of profibrotic state. sacubitril / valsartan 
decreased aldosterone, sST2, MMP-9, TIMP-1, and PINP. Changes in sacubitril / valasartan 
treated patients are indicated by green dashed boxes. 
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Table 1: Baseline Demographics 
Patients with baseline and 
follow-up biomarker data 
Enalapril Sacubitril/valsartan  
n=881 n=895  p-value 
    
Age (years) 
67   ± 10 67   ± 10 0.97 
Female sex 174     (20  %) 158     (18  %) 0.26 
Body Mass Index 29.8 ± 5.5 29.4 ± 5.5 0.18 
NYHA Class   0.94 
1 21      (2   %) 19      (2   %)   
2 647     (74  %) 670     (75  %)   
3 206     (23  %) 201     (22  %)   
4 5       (1   %) 5       (1   %)   
LV Ejection Fraction 31   ± 6 31   ± 6 0.78 
Prior use of ACEi  688     (78  %) 739     (83  %) 0.018 
Prior use of ARB 201     (23  %) 162     (18  %) 0.014 
Prior HF hospitalization 523     (59  %) 524     (59  %) 0.73 
Hypertension status 686     (78  %) 686     (77  %) 0.54 
Race   0.49 
White 843     (96  %) 857     (96  %)   
Black 24      (3   %) 20      (2   %)   
Asian 4       (0   %) 2       (0   %)   
Other 10      (1   %) 16      (2   %)   
Region   0.57 
North America 131     (15  %) 145     (16  %)   
Latin America 0       (0   %)  0       (0   %)   
Western Europe and Other 408     (46  %) 394     (44  %)   
Central Europe 342     (39  %) 356     (40  %)   
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Asia-Pacific 0       (0   %)  0       (0   %)   
Systolic Blood Pressure 123  ± 16 124  ± 16 0.22 
Diabetes Mellitus 355     (40  %) 350     (39  %) 0.61 
Heart Rate 72   ± 12 71   ± 12 0.25 
Ischemic Cardiomyopathy 565     (64  %) 574     (64  %) 1.00 
Prior Myocardial Infarction 422     (48  %) 444     (50  %) 0.47 
Prior Atrial Fibrillation 440     (50  %) 424     (47  %) 0.28 
Prior Stroke 98      (11  %) 80      (9   %) 0.13 
ICD 244     (28  %) 254     (28  %) 0.75 
CRT 100     (11  %) 90      (10  %) 0.38 
Diuretic 725     (82  %) 719     (80  %) 0.29 
Beta Blockers 840     (95  %) 855     (96  %) 0.85 
Digoxin 214     (24  %) 180     (20  %) 0.034 
Aldosterone 423     (48  %) 375     (42  %) 0.010 
Baseline Creatinine 1.2  ± 0.3 1.2  ± 0.3 0.55 
Baseline BNP (pg/ml) 216  [148 , 378 ] 225  [150 , 392 ] 0.31 
Baseline NTproBNP (pg/ml) 1423 [822 , 2756] 1457 [831 , 2816] 0.62 
hs-troponin T (ng/L) 16 [10, 25] 16 [10, 24] 0.54 
 
Abbreviations: ICD = implantable cardiac defibrillator, CRT = cardiac resynchronization 
therapy, LV = left ventricular, HF = heart failure, ACEi = angiotensin converting enzyme 
inhibitor, ARB = angiotensin receptor blocker, BNP = b-type natriuretic peptide, NTproBNP = 
n-terminal pro BNP, NYHA = New York heart association 
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Table 2: Baseline Biomarker Data 
 
Abbreviations: TIMP = tissue inhibitor of matrix metalloproteinase (MMP), PINP = n-terminal 
propeptide of collagen I and collagen III (PIIINP), IQR = interquartile range, ,  represent the 
directional differences between PARADIGM –HF patients and mean referent control values and 
the numerical value of that change. 
 
Marker  
PARADIGM-HF 
Median (IQR) 
Referent Controls 
Median (IQR) 
%Pts above/below 
Referent Control 
Median 
Aldosterone (pmol/L) 275 (174, 465) 200 (150, 225)  68% 
sST2 (ng/mL) 32 (25, 42) 20 (17, 26)  92% 
Galectin-3 (ng/mL) 17 (14, 21) 12 (9, 15)  88% 
MMP-2 (ng/mL) 135 (117, 158) 335 (323, 443)  97% 
MMP-9 (ng/mL) 64 (38, 126) 95 (90, 110)  66% 
TIMP-1 (ng/mL) 125 (105, 152) 72 (70, 75)  99% 
PINP (ng/mL) 36 (27, 48) 30 (25, 35)  65% 
PIIINP (ng/mL)  4.6 (3.6, 5.9) 3.5 (3.0, 4.0)  78% 
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Table 3: Relationships Between Biomarkers and Outcomes 
Marker Visit 
Median  
[IQ Range] 
Baseline levels vs outcomes 
HR (95% CI), p-value  
Log-transformed, per SD 
8-mo changes vs subsequent outcomes 
HR (95% CI), p-value, 
per 20% increase 
Primary outcome* CV Death* Primary outcome** CV Death** 
Aldo 
(pmol/L) 
Baseline 275 [173,464] 0.96 (0.87-1.07) 
p=0.47 
1.00 (0.87-1.16) 
p=0.97 
0.97 (0.93-1.01) 
p=0.16 
0.97 (0.92-1.02) 
p=0.27 
M8 243 [154,394] 
sST2 
(ng/mL) 
Baseline 32.2 [25.4,41.5] 1.16 (1.06-1.28) 
p=0.002 
1.18 (1.03-1.35) 
p=0.014 
1.14 (1.06-1.23) 
p<0.001 
1.05 (0.96-1.16) 
p=0.28 M8 31.0 [24.7,39.3] 
TIMP-1 
(ng/mL) 
Baseline 125 [106,152] 1.21 (1.07-1.37) 
p=0.003 
1.55 (1.28-1.87) 
p<0.001 
1.03 (0.94-1.13) 
p=0.50 
1.19 (1.05-1.35) 
p=0.006 M8 123 [102,152] 
MMP-2 
(ng/mL) 
Baseline 135 [117,158] 1.07 (0.96-1.20) 
p=0.24 
1.06 (0.90-1.26) 
p=0.49 
1.03 (0.94-1.12) 
p=0.54 
1.03 (0.92-1.15) 
p=0.62 M8 133 [114,153] 
MMP-9 
(ng/mL) 
Baseline 64.1 [38.2,126.2] 1.02 (0.92-1.14) 
p=0.66 
0.99 (0.85-1.16) 
p=0.94 
1.00 (0.97-1.03) 
p=0.93 
0.99 (0.95-1.04) 
p=0.79 M8 59.3 [35.7,109.2] 
Galectin-3 
(ng/mL) 
Baseline 17.1 [13.9,21.2] 1.05 (0.95-1.16) 
p=0.35 
1.04 (0.91-1.20) 
p=0.54 
1.09 (1.00-1.20) 
p=0.06 
1.08 (0.96-1.22) 
p=0.18 M8 17.9 [14.4,22.3] 
PINP 
(ng/mL) 
Baseline 36.0 [27.0,48.0] 0.98 (0.87-1.11) 
p=0.76 
1.04 (0.87-1.24) 
p=0.67 
1.01 (0.95-1.08) 
p=0.67 
1.03 (0.95-1.13) 
p=0.48 M8 34.5 [25.5,46.5] 
PIIINP 
(ng/mL)  
Baseline 4.7 [3.6, 5.9] 
1.11 (0.98-1.26) 
p=0.11 
1.24 (1.03-1.49) 
p=0.025 
1.05 (0.97-1.13) 
p=0.22 
1.04 (0.95-1.14) 
p=0.39 M8 4.5 [3.6, 5.8] 
*adjusted for treatment + baseline covariates (including log-transformed BNP, NT-proBNP, hsTnT) 
**adjusted for treatment + baseline covariates (including log-transformed BNP, NT-proBNP, hsTnT) + baseline biomarker value 
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Abbreviations: Baseline covariates = age, sex, geographic region, body mass index, New York Heart Association  class, left ventricular ejection fraction, 
prior heart failure hospitalization, hypertension, diabetes, ischemic etiology, prior myocardial infarction, atrial fibrillation, heart rate, systolic blood 
pressure, creatinine, prior stroke, implantable cardioverter defibrillator, cardiac resynchronization therapy, prior use of an angiotensin converting 
enzyme inhibitor, prior use of an angiotensin receptor blocker, diuretics, beta-blockers , digoxin, mineralocorticoid receptor antagonist, log(NT-
proBNP), BNP, log(hs-TnT); and randomized treatment (enalapril or sacubitril/valsartan). TIMP = tissue inhibitor of matrix metalloproteinase (MMP), 
PINP = n-terminal propeptide of collagen I and collagen III (PIIINP), 
  
There were no statistically significant treatment interactions (all p>0.05) 
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Appendix Table 1: Biomarker Standards 
 
Biomarker (unit) Manufacturer COV% LLOQ (or LOD) Reporting Range Matrix 
Aldosterone (pmol/L) DiaSorin (Liason) < 6% 52.90 52.9 – 1664.6  
TIMP-1  (ng/mL) R& D Systems < 7% 0.1 0.1 - 8000 EDTA plasma 
MMP-2 (pg/mL) Meso Scale Discovery < 15% 976 976 - 500,000 Li-Hep plasma 
MMP-9 (pg/mL) Meso Scale Discovery < 15% 488 488 - 1,000,000 Li-Hep plasma 
Galectin-3 (ng/mL) BG Medicine < 11.5% 1.74 1.74 – 96.6 serum 
sST-2 (ng/mL) Critical Diagnostics < 2.5% 3.13 ng/mL < 3.13 – 1600 serum 
PINP (ug/L) Orion RIA ≤ 10% 5 (LOD) 5 – 250 serum 
PIIINP (ug/L) Orion RIA ≤ 10% 1 (LOD) 1 – 50 serum 
NT-proBNP (pg/mL) Roche < 2.5% 8 < 8 - 35,000 Li-Hep plasma 
hsTnT (ng/mL) Roche (5th  generation) 
14.5% 
< 10% 
5 (LOD) 
13 (LLOQ) 
< 5 – 10,000 EDTA plasma 
 
Abbreviations: TIMP = tissue inhibitor of matrix metalloproteinase (MMP), PINP = n-terminal propeptide of collagen I and collagen III (PIIINP), 
hsTnT = high sensitivity troponin, CV = coefficient of variance, LOD = lower limit of detection (LOD), LLOQ = lower limit of quantification, 
EDTA = Ethylenediaminetetraacetic acid, Li Hep = lithium heparin. 
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Appendix Table 2: 
 
Biomarker Referent Control Reference Assay Method Antibody 
Aldosterone 
  
  
7-30 ng/dL (or 70-300 pg/mL) 22 Textbook on WebMD 
5.31 ± 3.8 ng/dL (mean±sd) (n=2157) (or 53±38 pg/mL) 23 Vitros analyzer, Ortho Clinical Diagnosis 
7-20 ng/dL (70-200 ng/mL) or 0.2-0.8 nmol/L (200-800 pmol/L) 24 ACP Lab Reference Ranges 
sST-2 20 (17, 26) ng/mL (median/iqr) 8 Presage immunoassay, Critical Diagnostics, San 
Diego 
Galectin-3 12 (9, 15) ng/mL (median/iqr) 8 Enzyme-linked immunosorbent assay, BG 
Medicine, Waltham, MA 
MMP-2 339.7 ± 9.3 ng/mL (mean±sem) (n=241) 7 Multiplex suspension array, MMP Base kit 
LMP000, BioPlex 200, BioRad Laboratories 
374.8 ± 35.7 ng/mL (mean±sem) (n=15) 14 Multiplex suspension array, MMP Base kit 
LMP000, BioPlex 200, BioRad Laboratories 
236.6 (217.6,275.3) ug/L (median/iqr) (n=49) 18 R&D Systems 
335 (323, 443) ng/mL (median/iqr) 8 Immunoassay (R&D Systems, Minneapolis, MN) 
MMP-9 95.0 ± 3.8 ng/mL (mean±sem) (n=241) 7 Multiplex suspension array, MMP Base kit 
LMP000, BioPlex 200, BioRad Laboratories 
121.1 ± 13.1 ng/mL (mean±sem) (n=15) 14 Multiplex suspension array, MMP Base kit 
LMP000, BioPlex 200, BioRad Laboratories 
58.8 (38.0,134.4) ug/L (median/iqr) (n=49) 18 R&D Systems 
145 ± 88 ug/L (mean±sd) (n=9) 19 ELISA, R&D Systems 
TIMP-1 72.2 ± 1.4 ng/mL (mean±sem) (n=241) 7 Multiplex suspension array, TIMP MSA kit 
LKT003, BioPlex 200, BioRad Laboratories 
106.3 ± 4.4 ng/mL (mean±sem) (n=15) 14 Multiplex suspension array, TIMP MSA kit 
LKT003, BioPlex 200, BioRad Laboratories 
827.7 ± 111.5 ug/L (mean±sd) (n=92) 15 ELISA (Amersham Pharmacia Biotech, UK) 
217.2 (203.3,245.2) ug/L (median/iqr) (n=49) 18 R&D Systems 
165 ± 67 ug/L (mean±sd) (n=9) 19 ELISA, R&D Systems 
634 ± 7 ng/mL (mean±sem) 20 GE Healthcare Life Sciences 
PINP 
  
  
  
37.1 ± 1.3 ng/mL (mean±sem) (n=241) 7 Radioimmunoassay 
46.6 ± 19.1 ug/L (mean±sd) (n=92) 15 Radioimmunoassay, Orion Diagnostica 
53.4 ± 25.9 ug/L (mean±sd) (n=25) 17 Radioimmunoassay, Abbott 
39.6 ± 17.4 ug/L (mean±sd) (n=9) 19 Radioimmunoassay, Abbott 
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PIIINP 7.2 ± 0.1 ng/mL (mean±sem) (n=241) 7 Radioimmunoassay 
3.5 ± 1.3 ug/L (mean±sd) (n=92) 15 Radioimmunoassay, Orion Diagnostica 
3.1 (2.4,4.0) ng/mL (median/iqr) (n=283) 16 Radioimmunoassay, Orion Diagnostica 
4.4 ± 1.1 ug/L (mean±sd) (n=25) 17 Radioimmunoassay, Abbott 
5.8 (4.4 ,7.0) ug/L (median/iqr) (n=49) 18 Radioimmunoassay, Orion Diagnostica 
6.5 (6.1, 8.2) ng/mL (median/iqr) 8 Quest Diagnostics, Valencia, CA 
4.1 ± 0.7 ug/L (mean±sd) (n=9) 19 Radioimmunoassay, Abbott 
457 (175-1160) pg/mL (median/iqr) 20 MyBioSource, San Diego 
3.4 ± 0.2 ug/L (mean±sem) (n=30) 21 Radioimmunoassay, Farmos Diagnostica 
 
Abbreviations: TIMP = tissue inhibitor of matrix metalloproteinase (MMP), PINP = n-terminal propeptide of collagen I and collagen III (PIIINP), 
Median (IQR) referent control data for PIIINP and MMP-2 were taken from a previously published study in which 241 subjects of age, sex, and race 
distribution similar to this study population were examined (7). However, these well-characterized subjects had no clinical, serological, or cardiac 
structural/functional abnormalities as evidenced by a normal echocardiography and 6-minute hall walk distance. Median (IQR) referent control data 
for Gal-3 were taken from a previously published study in which 1092 subjects of age, sex, and race distribution similar to this study population were 
examined (25). Median (IQR) referent control data for sST-2 were aggregated from previously published studies (including the Framingham study) 
in which subjects of age, sex, and race distribution similar to this study population were examined (26-29). Reported normal values for sST-2 were 
20 ng/mL (95% CI of 17-26 ng/mL), and for Gal-3 was 12 ng/mL (95% CI of 9-15 ng/mL) (8). Although small differences between men and women 
have been seen in the biomarkers described above, because the populations of both this study and the referent control populations have similar sex 
distribution, the referent control values listed in Appendix Table 2 represent the total referent population examined. 
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Appendix Table 3: Relationship Between Profibrotic Biomarker and Outcome: Independent effect of each Biomarker 
 
Marker 
Baseline levels vs outcomes 
HR (95% CI), p-value log transformed per SD 
Primary outcome* CV Death* 
Aldo 
(pmol/L) 
0.89 (0.78-1.01) 
p=0.07 
0.91 (0.76-1.09) 
p=0.30 
sST2 
(ng/mL) 
1.11 (0.98-1.25) 
p=0.09 
1.08 (0.91-1.29) 
p=0.37 
TIMP-1 
(ng/mL) 
1.20 (1.03-1.38) 
p=0.017 
1.43 (1.14-1.79) 
p=0.002 
MMP-2 
(ng/mL) 
1.02 (0.90-1.16) 
p=0.74 
1.00 (0.83-1.20) 
p=0.99 
MMP-9 
(ng/mL) 
1.02 (0.91-1.14) 
p=0.74 
1.01 (0.85-1.20) 
p=0.93 
Galectin-3 
(ng/mL) 
1.08 (0.95-1.23) 
p=0.26 
1.04 (0.86-1.26) 
p=0.67 
PINP 
(ng/mL) 
0.90 (0.77-1.04) 
p=0.16 
0.89 (0.72-1.11) 
p=0.32 
PIIINP 
(ng/mL) 
1.07 (0.91-1.25) 
p=0.44 
1.14 (0.90-1.44) 
p=0.29 
 
Abbreviations: *adjusted for treatment + baseline covariates (including BNP, NT-proBNP, hsTnT) + all 8 profibrotic biomarkers, 
TIMP = tissue inhibitor of matrix metalloproteinase (MMP), PINP = n-terminal propeptide of collagen I and collagen III (PIIINP), 
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Appendix Table 4: Compare c-statistic to determine if fibrosis biomarkers added independent value to prognosis. 
 
(treatment included in all) Primary Outcome CV Death 
M1: Baseline Covariates 0.66 0.67 
M2: M1 + BNP, NT-proBNP, hsTnT 0.71 0.70 
M3: M2 + TIMP-1 
0.72 
(p=0.08 vs M2) 
0.71 
(p=0.37 vs M2) 
M4: M2 + all 8 profibrotic biomakers 0.72 0.72 
M5: BNP, NT-proBNP, hsTnT + all 8 profibrotic biomarkers 
(i.e. M4 minus M1) 
0.70 0.68 
Abbreviations: BNP = b-type natriuretic peptide, NTproBNP = n-terminal pro BNP, TIMP = tissue inhibitor of matrix metalloproteinase (MMP), 
PINP = n-terminal propeptide of collagen I and collagen III (PIIINP), 
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Appendix Table 5: Baseline Demographics 
 
Patients in Paradigm-HF with 
biomarker vs no biomarker data 
No Baseline 
Biomarkers 
Baseline 
Biomarkers  
 
n=6332 n=2067  p-value 
    
Age (years) 
63 ± 12 67 ± 10 <0.001 
Female sex 1446    (23  %) 386     (19  %) <0.001 
Body Mass Index 27.7 ± 5.5 29.5 ± 5.4 <0.001 
NYHA Class   <0.001 
1 342     (5   %) 47      (2   %)  
2 4410    (70  %) 1509    (73  %)  
3 1520    (24  %) 498     (24  %)  
4 49      (1   %) 11      (1   %)  
LV Ejection Fraction 29   ± 6 30   ± 6 <0.001 
Prior use of ACEi  4865    (77  %) 1667    (81  %) <0.001 
Prior use of ARB 1478    (23  %) 414     (20  %) 0.002 
Prior HF hospitalization 4035    (64  %) 1239    (60  %) 0.001 
Hypertension status 4333    (68  %) 1607    (78  %) <0.001 
Race   <0.001 
White 3582    (57  %) 1962    (95  %)  
Black 364     (6   %) 64      (3   %)  
Asian 1501    (24  %) 8       (0   %)  
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Other 885     (14  %) 33      (2   %)  
Region   <0.001 
North America 265     (4   %) 337     (16  %)  
Latin America 1433    (23  %) 0       (0   %)  
Western Europe and Other 1112    (18  %) 939     (45  %)  
Central/Eastern Europe 2035    (32  %) 791     (38  %)  
Asia-Pacific 1487    (23  %) 0       (0   %)  
Systolic Blood Pressure 121  ± 15 123  ± 16 <0.001 
Diabetes Mellitus 2089    (33  %) 818     (40  %) <0.001 
Heart Rate 73   ± 12 71   ± 12 <0.001 
Ischemic Cardiomyopathy 3711    (59  %) 1325    (64  %) <0.001 
Prior Myocardial Infarction 2628    (42  %) 1006    (49  %) <0.001 
Prior Atrial Fibrillation 2091    (33  %) 1000    (48  %) <0.001 
Prior Stroke 515     (8   %) 210     (10  %) 0.004 
ICD 656     (10  %) 587     (28  %) <0.001 
CRT 345     (5   %) 229     (11  %) <0.001 
Diuretic 5045    (80  %) 1693    (82  %) 0.027 
Beta Blockers 5841    (92  %) 1970    (95  %) <0.001 
Digoxin 2074    (33  %) 465     (22  %) <0.001 
Aldosterone 3740    (59  %) 931     (45  %) <0.001 
Baseline Creatinine 1.1  ± 0.3 1.2  ± 0.3 <0.001 
45 9/28/2018 
Baseline BNP (pg/ml) 261  [154 , 496 ] 229  [154 , 400 ] <0.001 
Baseline NTproBNP (pg/ml) 1665 [903 , 3385] 1485 [852 , 2907] <0.001 
hs-troponin T (ng/L) 24  [17, 31] 16 [11, 25] 0.40 
Abbreviations: ICD = implantable cardiac defibrillator, CRT = cardiac resynchronization therapy, LV = left ventricular, HF = heart 
failure, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BNP = b-type natriuretic peptide, 
NTproBNP = n-terminal pro BNP, NYHA = New York heart association 
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Appendix Table 6: Baseline Demographics 
Patients from full Paradigm-
HF cohort vs those with 
baseline biomarkers vs those 
with both baseline and follow-
up biomarkers 
PARADIGM-HF 
cohort 
Baseline 
Biomarkers 
Full cohort 
vs Baseline 
biomarker 
cohort 
Baseline + 
follow-up 
biomarkers 
Baseline 
only vs 
Baseline + 
follow-up 
 n=8399 n=2067 p-value n=1776 p-value 
      
Age (years) 64   ± 11 67 ± 10 <0.001 67   ± 10 0.027 
Female sex 1832    (22  %) 386     (19  %) <0.001 332     (19  %) 0.96 
Body Mass Index 28.2 ± 5.5 29.5 ± 5.4 <0.001 29.6 ± 5.5 0.005 
NYHA Class   <0.001  0.021 
1 389     (5   %) 47      (2   %)  40      (2   %)  
2 5919    (71  %) 1509    (73  %)  1317    (74  %)  
3 2018    (24  %) 498     (24  %)  407     (23  %)  
4 60      (1   %) 11      (1   %)  10      (1   %)  
LV Ejection Fraction 29   ± 6 30   ± 6 <0.001 31   ± 6 0.001 
Prior use of ACEi 6532    (78  %) 1667    (81  %) <0.001 1427    (80  %) 0.39 
Prior use of ARB 1892    (23  %) 414     (20  %) 0.002 363     (20  %) 0.25 
Prior HF hospitalization 5274    (63  %) 1239    (60  %) 0.001 1047    (59  %) 0.023 
Hypertension status 5940    (71  %) 1607    (78  %) <0.001 1372    (77  %) 0.18 
Race   <0.001  <0.001 
White 5544    (66  %) 1962    (95  %)  1700    (96  %)  
Black 428     (5   %) 64      (3   %)  44      (2   %)  
Asian 1509    (18  %) 8       (0   %)  6       (0   %)  
Other 918     (11  %) 33      (2   %)  26      (1   %)  
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Region   <0.001  0.016 
North America 602     (7   %) 337     (16  %)  276     (16  %)  
Latin America 1433    (17  %) 0       (0   %)  0       (0   %)  
Western Europe and Other 2051    (24  %) 939     (45  %)  802     (45  %)  
Central Europe 2826    (34  %) 791     (38  %)  698     (39  %)  
Asia-Pacific 1487    (18  %) 0       (0   %)  0       (0   %)  
Systolic Blood Pressure 121  ± 15 123  ± 16 <0.001 123  ± 16 0.21 
Diabetes Mellitus 2907    (35  %) 818     (40  %) <0.001 705     (40  %) 0.78 
Heart Rate 72   ± 12 71   ± 12 <0.001 71   ± 12 0.08 
Ischaemic Cardiomyopathy 5036    (60  %) 1325    (64  %) <0.001 1139    (64  %) 0.94 
Prior Myocardial Infarction 3634    (43  %) 1006    (49  %) <0.001 866     (49  %) 0.84 
Prior Atrial Fibrillation 3091    (37  %) 1000    (48  %) <0.001 864     (49  %) 0.54 
Prior Stroke 725     (9   %) 210     (10  %) 0.004 178     (10  %) 0.61 
ICD 1243    (15  %) 587     (28  %) <0.001 498     (28  %) 0.37 
CRT 574     (7   %) 229     (11  %) <0.001 190     (11  %) 0.17 
Diuretic 6738    (80  %) 1693    (82  %) 0.027 1444    (81  %) 0.08 
Beta Blockers 7811    (93  %) 1970    (95  %) <0.001 1695    (95  %) 0.48 
Digoxin 2539    (30  %) 465     (22  %) <0.001 394     (22  %) 0.40 
Aldosterone 4671    (56  %) 931     (45  %) <0.001 798     (45  %) 0.81 
Baseline Creatinine 1.1  ± 0.3 1.2  ± 0.3 <0.001 1.2  ± 0.3 <0.001 
Baseline BNP (pg/ml) 253  [154 , 468 ] 229  [154 , 400 ] <0.001 221  [149 , 384 ] <0.001 
Baseline NTproBNP (pg/ml) 1612 [886 , 3224] 1485 [852 , 2907] <0.001 1444 [827 , 2788] <0.001 
hs-troponin T (ng/L) 17 [11, 25] 16 [11, 25] 0.40 16 [10, 24] <0.001 
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Abbreviations: ICD = implantable cardiac defibrillator, CRT = cardiac resynchronization therapy, LV = left ventricular, HF = heart 
failure, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, BNP = b-type natriuretic peptide, 
NTproBNP = n-terminal pro BNP, NYHA = New York heart association 
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Appendix Table 7: Effects of sacubitril/valsartan on profibrotic biomarkers adjusted for systolic blood pressure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Marker Visit  Baseline to 8 Mo change: 
    *Adjusted for baseline biomarker ** Additionally adjusted for 
 baseline SBP + SBP change 
  Enalapril Sacubitril/ 
valsartan 
Sacubitril/ 
valsartan effect* 
P-value* Sacubitril/ 
valsartan effect** 
P-value** 
Aldo 
(pmol/L)  
IQR [-34%, +26%] [-37%, +21%]  --   
% 
change 
-10.3% -14.2% -6% (-11%, -1%) 0.020 -7% (-12%, -2%) 0.007 
sST2 
(ng/ml) 
IQR [-14%, +18%] [-18%, +10%]  --  -- 
% 
change 
+0.8% -5.5% -7% (-9%, -4%) <0.001 -6% (-9%, -4%) <0.001 
TIMP-1 
(ng/ml) 
IQR [-11%, +15%] [-15%, +10%]  --  -- 
% 
change 
+0.3% -3.6% -4% (-7%, -1%) 0.003 -5% (-7%, -2%) 0.001 
MMP-2 IQR [-10%, +7.6%] [-11%, +7.4%]     
% 
change 
-0.8% -2.1% -1% (-4%, +1%) 0.36 -1% (-4%, +2%) 0.46 
MMP-9 IQR [-37%, +54%] [-43%, +47%]     
% 
change 
-3.0% -10.5% -8% (-14%, -2%) 0.010 -9% (-15%, -3%) 0.006 
Gal-3 IQR [-7.4%, +23%] [-8.6%, +21%]     
% 
change 
+5.3% +4.7% -1% (-3%, +2%) 0.51 -1% (-4%, +1%) 0.24 
PINP IQR [-20%, +26%] [-26%, +18%]     
% 
change 
+0.6% -6.2% -6% (-10%, -3%) <0.001 -6% (-10%, -3%) <0.001 
PIIINP IQR [-22%, +22%] [-22%, +18%]     
% 
change 
-1.7% -4.5% -3% (-6%, 0%) 0.086 -3% (-6%, 0%) 0.090 
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Figure 1.  
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Central Illustration Figure 4. 
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